About MELAGENIX
MELAGENIX is a company based in Koln (Germany) founded in 2017 by Daniel Von Janowski, Georg Brunner, and Anton Strobe. MELAGENIX has raised $8.92 million across 1 funding round from investors including BayBG Venture Capital and MIG Capital. MELAGENIX operates in a competitive market with competitors including Castle Biosciences, DermTech, AMLo Biosciences, Haut and Michelson Diagnostics, among others.
- Headquarter Koln, Germany
- Founders Daniel Von Janowski, Georg Brunner, Anton Strobe
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Neracare Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.92 M (USD)
in 1 rounds
-
Latest Funding Round
$8.92 M (USD), Series A
Mar 05, 2020
-
Investors
BayBG Venture Capital
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of MELAGENIX
MELAGENIX has successfully raised a total of $8.92M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.92 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MELAGENIX
MELAGENIX has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include BayBG Venture Capital and MIG Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in series A to series B stages
|
Locked | Locked | Locked | |
|
VC Firm funding companies in Europe
|
Locked | Locked | Locked |
Investor details for MELAGENIX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MELAGENIX
Investment portfolio details for MELAGENIX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MELAGENIX
Detailed financials for MELAGENIX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Melagenix Comparisons
Peer comparison for MELAGENIX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MELAGENIX
MELAGENIX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Castle Biosciences, DermTech, AMLo Biosciences, Haut and Michelson Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Adhesive patch biopsies for skin cancer detection are provided.
|
|
| Locked | Locked | Locked |
Prognostic tests for early-stage melanoma detection are developed.
|
|
| Locked | Locked | Locked |
SaaS solutions using AI for skincare businesses are provided.
|
|
| Locked | Locked | Locked |
Develops and supplies VivoSight OCT scanners for non-invasive medical diagnostics.
|
Detailed competitors of MELAGENIX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Melagenix
Complete news archive for MELAGENIX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MELAGENIX
MELAGENIX was founded in 2017 and raised its 1st funding round 3 years after it was founded.
MELAGENIX is headquartered in Koln, Germany. It is registered at Koln, North Rhine-westphalia, Germany.
MELAGENIX is a funded company, having raised a total of $8.92M across 1 funding round to date.
Founded in 2017 in Cologne, Germany, MELAGENIX operates in the biotechnology sector, focusing on molecular diagnostics for oncology. RT-PCR-based assays are developed to detect melanoma and assess AJCC staging in patients at clinical trial stages I-III. Tumor-specific information is provided to support treatment decisions, with operations centered on advancing diagnostic tools for skin cancer management.
MELAGENIX's top competitors include DermTech, AMLo Biosciences and Castle Biosciences.
MELAGENIX has 2 investors. Key investors include BayBG Venture Capital, and MIG Capital.